We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.
From its small beginnings in 1867, Mewburn Ellis has grown into a vibrant, outward-looking partnership with innovation at its core. As science and technology continue to transform the way we live, we look forward to a future as positive and successful as our past.
It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU. We consider the effect of the decision on intellectual property.
The Unitary Patent (UP) and Unified Patent Court (UPC) are due to come into entry in the near future and aim to bring a single patent right and single patent litigation forum to Europe.
With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.
The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.
t: +44 (0)20 7776 5300
t: +44 (0)117 945 1234
t: +44 (0)1223 420383
t: +44 (0)161 247 7722
Stephen Hodsdon will be speaking about IP strategies in Europe after Brexit at the Patinex 2017 conference that takes place from 7 -8 September 2017 in Seoul, Korea.
Cambridge Enterprise, the commercialisation arm of the University of Cambridge, has licensed key technology to specialist growth factor manufacturer Qkine Ltd for Activin A production.